Patients with secondary consequence of intracranial pathology should be examined frequently for progression or recurrence of the primary disease process. In patients with endocrine disorders, including winstrol results, can occur slippage of the femoral head, which can manifest the development of a limp or complaints of pain in the knee or hip. In patients with (pan) hypopituitarism standard replacement therapy must be closely monitored. In the presence of severe or recurrent headache, visual problems, nausea and / or vomiting is recommended fundus examination to detect edema of the optic nerve papilla. If edema is confirmed, it is necessary to assume the presence of benign intracranial hypertension, and, if appropriate, GH treatment should be interrupted. Currently, there is insufficient evidence to be guided only by clinical criteria for making decisions about patients with intracranial hypertension in the resolution stage. If GH treatment is restarted again, careful monitoring of intracranial hypertension symptoms.
A small number of patients with some of whom were treated with somatropin, reported leukemia. Evaluation of 10-year-old world experience revealed no increased risk of development of leukemia during somatropin treatment. In patients in complete remission after tumors or malignant disease, GH therapy has not been associated with an increased frequency of relapses. Nonetheless, after the start of treatment, patients attained a complete remission of malignant diseases should be carefully kontrollirovat for relapse.
It is recommended that monitoring of adult patients with GHD, receiving the drug winstrol results, I spent endocrinologist with special experience in pituitary disease.
GHD in adults is a lifelong disease and requires appropriate treatment. However, in patients older than 60 years and in patients with more than five years’ experience in the treatment of therapy is still limited.
Interaction with other drugs and other forms of interaction:
Concomitant glucocorticoid therapy may inhibit growth by inhibiting the effect of the drug . GH effect on the final growth may be mediated by other hormones concomitant therapy, for example, gonadotropins, anabolic steroids, estrogens itireoidnymi hormones.
In patients receiving insulin treatment, the appointment of the drug Norditropin® NordiLet® may need dose adjustment of insulin.
Use during pregnancy and lactation:
Currently, there is insufficient data on the safety of growth hormone during pregnancy. It is necessary to take into account the fact that the possibility is not excluded secretion of growth hormone from the mother’s milk.
There may be a delay in fluid and peripheral edema, especially adults, may experience carpal tunnel syndrome. Symptoms usually transitory and dose dependent, but may require dose reduction. Adults can also meet easy arthralgia, muscle pain or parasthesia, but they are usually short-lived and self-cropped. Adverse reactions in children are rare. The integrated database of drug contains data on children treated for almost eight years. Headache communicated with a frequency of 0.04 / patient / year. During treatment with recorded a few rare cases of benign intracranial hypertension. Formation of antibodies to growth hormone during treatment are rare.
During treatment with Norditropin® NordiLet® can meet local reactions at the injection sites.
Acute overdose may lead initially to hypoglycemia and subsequently to hyperglycemia. These reduced levels of glucose were determined biochemically without clinical signs of hypoglycemia. Long-term overdose could result in signs and winstrol results symptoms similar to the known effects of excess human GH.